News
Genetically targeted technologies can improve heart disease treatment, but only with legislation that supports continued research and development.
Some genetically targeted therapies are classified in the IRA as small-molecule drugs, limiting the incentive for biotech companies to pursue them, writes Alnylam CEO.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results